Characterizing colorectal cancer spread to the peritoneum
Official title: Molecular Characterisation of Colorectal Cancer Peritoneal Metastases: Genomic and Transcriptomic Analysis With Correlation of Clinical Outcomes
Run by The Christie NHS Foundation Trust · NCT05513716 · Data updated 2026-11-12
This study is trying to understand how colorectal cancer spreads to the abdominal lining by looking at tumor cells from patients to see if certain genetic changes can help predict how well treatments will work.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | The Christie NHS Foundation Trust Academic / other |
| Locations | 1 site (Manchester) |
| Status | Recruiting |
| Started | February 4, 2024 |
| Main results expected | July 3, 2025 |
| Study ends | July 3, 2025 |
| Registry record updated | January 1, 2025 |
| Trial ID | NCT05513716 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with colorectal cancer and have colorectal peritoneal metastases, and who have undergone cytoreductive surgery.
✕Probably not a fit
Patients who have not had cytoreductive surgery or do not have available archival tumor tissue will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to analyze tumor cells and their environment in colorectal cancer peritoneal metastases to understand the molecular changes that lead to this condition. By conducting genetic profiling on archived tissue from patients who have undergone surgery for colorectal cancer peritoneal metastases, the study seeks to identify mutation patterns that could predict treatment responses and survival outcomes. The findings will be compared with clinical characteristics to enhance personalized treatment strategies and potentially improve patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with colorectal cancer peritoneal metastases.
How similar studies have gone: While there has been limited research on the molecular characterization of colorectal cancer peritoneal metastases, similar studies in other cancer types have shown promise in identifying biomarkers and improving treatment strategies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply: 1. Patients ≥ 18 years old who have been diagnosed with colorectal cancer and have colorectal peritoneal metastases, 2. have had cytoreductive surgery at the Christie 3. have availability of archival tumour tissue (paired CRC and CRPM) Exclusion Criteria: * None
Where it's running
-
Christie Hospital NHS Foundation Trust
Manchester, United Kingdom Recruiting
Study contacts
- Study coordinator: Richa Garvia, Ms
- Email: removed_due_to_spam@email.com
- Phone: 0161 446 3000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases
This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.
-
Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers
This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.
-
COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer
This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.
-
ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer
This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.
-
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial will test whether regorafenib given as a less-intensive, personalized second-line option can preserve quality of life and extend survival for people with RAS‑mutant metastatic colorectal cancer who had a long first-line benefit or have only one metastatic site.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.